Original Article

You have full text access to this OnlineOpen article

Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals†‡

  1. Alina Burgi M.P.H.1,
  2. Stephanie Brodine M.D.1,
  3. Scott Wegner M.D.2,3,
  4. Mark Milazzo2,3,
  5. Mark R. Wallace M.D.3,4,
  6. Katherine Spooner M.D.3,5,
  7. David L. Blazes M.D., M.P.H.3,6,
  8. Brian K. Agan M.D.3,7,
  9. Adam Armstrong D.O.3,8,
  10. Susan Fraser M.D.3,9,
  11. Nancy F. Crum M.D., M.P.H.3,4,§,*

Article first published online: 15 AUG 2005

DOI: 10.1002/cncr.21334

Issue

Cancer

Cancer

Volume 104, Issue 7, pages 1505–1511, 1 October 2005

Additional Information

How to Cite

Burgi, A., Brodine, S., Wegner, S., Milazzo, M., Wallace, M. R., Spooner, K., Blazes, D. L., Agan, B. K., Armstrong, A., Fraser, S. and Crum, N. F. (2005), Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer, 104: 1505–1511. doi: 10.1002/cncr.21334

Author Information

  1. 1

    Graduate School of Public Health, San Diego State University, San Diego, California

  2. 2

    United States Military HIV Research Program, Rockville, Maryland

  3. 3

    Tri-Service AIDS Clinical Consortium, Rockville, Maryland

  4. 4

    Infectious Diseases Division, Naval Medical Center, San Diego, California

  5. 5

    Infectious Diseases Division, Walter Reed Army Medical Center, Washington, DC

  6. 6

    Infectious Diseases Division, National Naval Medical Center, Bethesda, Maryland

  7. 7

    Infectious Diseases Division, Wilford Hall United States Air Force Medical Center, Lackland Air Force Base, Texas

  8. 8

    Infectious Diseases Division, Naval Medical Center Portsmouth, Portsmouth, Virginia

  9. 9

    Infectious Diseases Division, Tripler Army Medical Center, Honolulu, Hawaii

  1. §

    Fax: (619) 532-8137

*c/o Clinical Investigation Department (KCA), Naval Medical Center San Diego, 34800 Bob Wilson Drive, Suite 5, San Diego, CA 92134-1005

  1. †

    This is a U.S. government work and, as such, is in the public domain in the United States of America.

  2. ‡

    Presented in condensed form as abstract 886 at the 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, Massachusetts, September 30–October 3, 2004.

Publication History

  1. Issue published online: 17 SEP 2005
  2. Article first published online: 15 AUG 2005
  3. Manuscript Accepted: 11 MAY 2005
  4. Manuscript Received: 26 APR 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (88K)

REFERENCES

  • 1
    Levine AM. AIDS-related malignancies: the emerging epidemic. J Natl Cancer Inst. 1993; 85: 1382–1397.
  • 2
    Stine GJ. AIDS update 2003. Upper Saddle River: Prentice Hall, 2003.
  • 3
    Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41(RR-17): 1–19.
  • 4
    Cooley TP. Non-AIDS-defining cancer in HIV-infected people. Hematol Oncol Clin North Am. 2003; 17: 889–899.
  • 5
    Grulich AE, Li Y, McDonald A, et al. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 2002; 16: 1155–1161.
  • 6
    Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J AIDS. 2003; 32: 527–533.
  • 7
    Wegner SA, Wallace MR, Aronson NE, et al. RV-125 Centers for Education and Research on Therapeutics Study Team. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis. 2004; 38: 723–730.
  • 8
    Crum NF, Wallace MR, Stephan K, et al. Correlates of human herpesvirus-8 seropositivity among U.S. military members recently infected with human immunodeficiency virus. Sex Transm Dis. 2003; 30: 713–718.
  • 9
    National Program of Cancer Registries, Surveillance, Epidemiology, and End Results Program. United States cancer statistics, 2000 incidence report by primary site, males and females, and age-adjusted. Available at: http://www.cdc.gov/cancer/npcr/USCS/2000/cancer_incidence.htm (accessed August 10, 2003).
  • 10
    Ramsey ML. Basal cell cancer. Available at: http://www.emedicine.com/derm/topic47.htm (accessed January 26, 2005).
  • 11
    Goldman G. Squamous cell cancer. Available at: http://www.emedicine.com/derm/topic401.htm (accessed January 26, 2005).
  • 12
    Jones JL, Hanson DL, Dworkin MS, et al. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected person. Adult/Adolescent Spectrum of HIV Disease Project group. J AIDS. 1999; 21: S11–S17.
  • 13
    Grulich AE. AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy. J AIDS. 1999; 21: S27–S30.
  • 14
    Rabkin CS, Testa MA, Huang J, Von Roenn JH. Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS clinical trial group study participants. J AIDS. 1999; 21: S31–S33.
  • 15
    Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies an international perspective. Hematol Oncol Clin North Am. 2003; 17: 673–96.
  • 16
    Patel P, Novak RM, Tong T, et al. Incidence of non-AIDS-defining malignancies in the HIV outpatient study [abstract 81]. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, California, February 8–11, 2004.
  • 17
    Nutankalva L, McNeil JI, Frederick WR, Reddy RB, Howard University Hospital, Washington, DC. Malignancies in HIV: pre- and post-antiretroviral therapy [abstract 885]. The 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, September 30 through October 3, 2004.
  • 18
    Bedimo R, Chen RY, Accortt NA, et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989–2002. Clin Infect Dis. 2004; 39: 1380–1384.
  • 19
    Stein M, O'Sullivan P, Wachtel T, et al. Causes of death in persons with human immunodeficiency virus infection. Am J Med. 1992; 93: 387–390.
  • 20
    Bonnet F, Lewden C, May D, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer. 2004; 101: 317–324.
    Direct Link:
  • 21
    Trubowitz P, Gates A, Kaplan L. Non-AIDS-defining malignancies. In: SparanoJA, editor. HIV and HTLV-1 associated malignancies. Boston: Klumer Academic Publishers, 2001: 303–328.
  • 22
    Dal Maso L, Franceschi S, Polesel J, et al. Cancer and AIDS Registry Linkage Study. Risk of cancer in persons with AIDS in Italy, 1985–1998. Br J Cancer. 2003; 89: 94–100.
  • 23
    Voutsadakis IA, Silverman LR. Breast cancer in HIV-positive women: a report of four cases and review of the literature. Cancer Invest. 2002; 20: 452–457.
  • 24
    Rodrigues LK, Klencke BJ, Vin-Christian K, et al. Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol. 2002; 138: 765–770.
  • 25
    Lobo DV, Chu P, Grekin RC, Berger TG. Nonmelanoma skin cancers and infection with the human immunodeficiency virus. Arch Dermatol. 1992; 128: 623–627.
  • 26
    Smith KJ, Skelton HG, Yeager J, et al. Cutaneous neoplasms in a military population of HIV-1 positive patients: Military Medical Consortium of the Advancement of Retroviral Research. J Am Acad Dermatol. 1993; 29: 400–406.
  • 27
    Crum NF, Spencer CR, Amling CL. Prostate carcinoma among men with human immunodeficiency virus infection. Cancer. 2004; 101: 294–299.
    Direct Link:
  • 28
    Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med. 2003; 138: 453–459.
  • 29
    El-Solh A, Kumar NM, Nair MP, et al. An RGD containing peptide from HIV-1 tat (65–80) modulates protooncogene expression in human bronchoalveolar carcinoma cell line, A549. Immunol Invest. 1997; 26: 351–370.
  • 30
    Kramer-Hammerle S, Kohleisen B, Hohenadl C, et al. HIV type 1 Nef promotes neoplastic transformation of immortalized neural cells. AIDS Res Hum Retroviruses. 2001; 17: 597–602.
  • 31
    De Falco G, Bellan C, Lazzi S, et al. Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene. 2003; 22: 6214–6219.
  • 32
    Ensoli B, Gendelman N, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature. 1994; 371: 674–680.
  • 33
    Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001; 285: 1736–1745.
  • 34
    Sullivan PS, Juhasz M, Brooks J, Wolfe M, and the Adult/Adolescent Spectrum of HIV Disease Study Group, CDC, Atlanta. Incidence and association of anorectal cancers in persons with HIV infection [abstract 777]. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, California, February 8–11, 2004.
  • 35
    Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003; 21: 3447–3453.
  • 36
    Meng Q, Walker DM, Olivero OA, et al. Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci USA. 2000; 97: 12667–12671.
  • 37
    American Cancer Society. Cancer facts and figures, 2002. Available at: http://www.cancer.org/downloads/STT/cancerfacts&figures2002tm.pdf (accessed February 2, 2005).
View Full Article (HTML) Get PDF (88K)